Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Deciphera Pharmaceuticals

Evaluate

Thumbnail
September 14, 2022

Esmo 2022 movers – Kras backfires

Inhibition of Kras dominated Esmo, though probably not in the way some had hoped.

Thumbnail
August 22, 2022

Esmo 2022 preview – duelling datasets

Article image
Vantage logo
November 05, 2021

Deciphera’s pipe dream dies

Article image
Vantage logo
September 28, 2021

Biotech’s key fourth-quarter data 

Deciphera, Allakos and Uniqure are all set for important data disclosures.

Article image
Vantage logo
May 11, 2021

Fortunes diverge for solo drug launchers

A solo drug launch is a testing time for a small company, made even tougher by the pandemic.

Article image
Vantage logo
June 02, 2020

US FDA approval tracker: several early decisions in May

Last month the FDA greenlit four oncology approvals early and the first GnRH antagonist in uterine fibroids.

Article image
Vantage logo
May 18, 2020

Deciphera completes its Blueprint rout

Article image
Vantage logo
April 28, 2020

Blueprint’s voyage ends in disaster

The failure of a crucial pivotal study consigns Blueprint’s lead drug, Ayvakit, to a tiny niche.

Article image
Vantage logo
January 14, 2020

Market feeling frothy? You might be right

Article image
Vantage logo
January 10, 2020

Blueprint beats Deciphera to the punch

In the battle between two Kit/PDGFRα kinase inhibitors first blood goes to Blueprint’s avapritinib.

Article image
Vantage logo
September 05, 2019

Esmo 2019 preview – Parps on parade

Among small-molecule approaches Europe’s premier oncology conference gives star billing to three Parp inhibitors in ovarian cancer.

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

May 15, 2023

Pharma’s Biggest Spenders 2022 Infographic

May 03, 2023

Gene Editing: Overhyped or Unstoppable Tide?

View more...

Editor's Picks

Vantage logo
May 16, 2023

Heightened US antitrust fears rattle biopharma

Vantage logo
May 11, 2023

2023’s biggest launches: the story so far

Vantage logo
May 17, 2023

Viking’s Voyage is not over yet

Vantage logo
May 09, 2023

Gene editing: overhyped or unstoppable tide?

Vantage logo
May 16, 2023

A slow (and low) year for FDA approvals

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up